or search on
|Title:||The impact of specialists on prescribing by general practitioners|
|Authors:||Robertson J; Fryer JL; O'Connell DL; Sprogis A; Henry DA|
|Keywords:||Adult; Humans; Interprofessional Relations; Male; Middle Aged; New South Wales; Other; pharmacology; Physician's Practice Patterns; Prescriptions; Prescriptions,Drug; Aged; Referral and Consultation; Research Support,Non-U.S.Gov't; Specialties,Medical; statistics & numerical data; therapy; Aged,80 and over; Cross-Sectional Studies; Data Collection; Design; Drug Utilization; Family Practice; Female|
|Journal Title:||Medical Journal of Australia|
|Page number start:||407|
|Page number end:||411|
|Abstract:||OBJECTIVE: To investigate the direct impact of specialists on prescribing by general practitioners. DESIGN: Cross-sectional, prescription-based study. SUBJECTS AND SETTING: 88 GPs in the Hunter Urban Division of General Practice, Hunter Valley, NSW. MAIN OUTCOME MEASURE: Proportions of specialist-initiated prescriptions for eight commonly prescribed drug classes. RESULTS: The proportion of specialist-initiated prescriptions was greatest for proton pump inhibitors (85%), and lowest for diuretics (8%), newer antidepressants (10%) and H2-receptor antagonists (13%). Specialists initiated 29% of prescriptions for beta-blockers, 26% for calcium-channel blockers, 20% for statins and 19% for angiotensin-converting enzyme inhibitors or angiotensin II antagonists. Specialists were more likely to have been involved in starting therapy with metoprolol than other beta-blockers (51% v 23%) and diltiazem than other calcium-channel blockers (48% v 19%), and this was related to indication for treatment. In contrast, prescriptions for the more recently introduced drugs (angiotensin II antagonists and atorvastatin) were not more likely to have been specialist-initiated than prescriptions for established angiotensin-converting enzyme inhibitors and statins. CONCLUSIONS: The direct impact of specialists on prescribing in the Hunter Urban Division of General Practice is substantial and varies with the drug class. This highlights the need to engage both GPs and specialists in efforts to improve prescribing practices|
|Division:||Cancer Research Division|
|Appears in Collections:||Research Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.